AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

01/03/2023 - 08:00 AM

NORTH CHICAGO, Ill., Jan. 3, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. Richard A. Gonzalez, chairman and chief executive officer, will present at 5:00 p.m. CT.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and women's health, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301711230.html

SOURCE AbbVie

ABBVIE INC.

NYSE:ABBV

ABBV Rankings

#30 Ranked by Market Cap

#886 Ranked by Dividends

ABBV Latest News

Apr 26, 2024

AbbVie Reports First-Quarter 2024 Financial Results

Apr 25, 2024

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study

Apr 23, 2024

Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands

Apr 18, 2024

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

Apr 12, 2024

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

ABBV Stock Data

Market Cap 290.01B

Float 1.76B

Insiders Ownership 0.11%

Institutions Ownership 71.92%

Short Percent 0.74%

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

Country United States of America

City NORTH CHICAGO

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

Trending News